Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake

Eli Lilly's new oral weight-loss drug, Foundayo, was prescribed 7,335 times in the U.S. in ​the fourth week, a modest uptake compared to rival ‌Novo Nordisk's Wegovy pill, analysts said.

Reuters • 19 hours ago

Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off

Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?

Investors Business Daily • 20 hours ago

Retatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLP

Eli Lilly's next-generation weight-loss drug, Retatrutide, could hit the shelves soon. Though the treatment has yet to attain FDA approval, demand is already so heavy that consumers are going to the black market to buy it.

Investors Business Daily • May 7, 2026

How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter

IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly.

Investors Business Daily • May 7, 2026

Here's Why Eli Lilly (LLY) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • May 7, 2026

Novo and Lilly gain on signs weight-loss pills could expand the market

Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the ​market to millions more patients and help counter pricing pressure.

Reuters • May 7, 2026

My Top Obesity Stock to Buy and Hold

Eli Lilly's Zepbound is already generating billions of dollars in revenue, making it the clear leader in a rapidly expanding market. Lilly's ability to produce and deliver creates a hurdle that smaller competitors can't easily overcome.

The Motley Fool • May 7, 2026

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up nearly 30%, while NVO has plummeted more than 30%.

MarketBeat • May 7, 2026

Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.

While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.

WSJ • May 7, 2026

Lilly commits additional $4.5 billion across Indiana manufacturing sites

Eli Lilly ​said on ‌Wednesday it would ​commit ​an additional $4.5 billion ⁠investment across ​two ​of its three sites in ​Indiana, ​bringing the company's ‌total ⁠capital expansion commitments in the ​state ​since ⁠2020 to ​more ​than $21 ⁠billion.

Reuters • May 6, 2026